福島 俊洋 ふくしま としひろ 先生

来歴等

略歴

1986年 福井医科大学医学部 卒業
1993年 福井医科大学医学部大学院 修了 医学博士取得
1993年 福井医科大学第1内科 助手
2000年 国立金沢病院内科 医師
2002年 金沢医科大学血液免疫内科 講師
2005年 金沢医科大学血液免疫内科 助教授
2007年 金沢医科大学血液免疫内科 准教授
2015年 金沢医科大学血液免疫内科 特任教授
2018年 金沢医科大学病院臨床試験治験センター 部長

論文

• Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second line treatment. Clin Lymp Myel & Leuk 18, 353-360, 2018

  Okada M, Fukushima T et al,

• Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103, 686-692, 2016

  Masaki Y, Fukushima T et al,

• Isolation of vascular smooth muscle antigen-reactive CD4(+)αβTh1 clones that induce pulmonary vasculitis in MRL/Mp-Fas(+/+) mice. Cell Immunol 303, 50-54, 2016

  Fujita Y, Fukushima T et al,

• Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. Med Oncol 32, 232, 2015

  Sakai T, Fukushima T et al,

• Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. J Infect Chemother 21, 16-22, 2015

  Nakane T, Fukushima T et al,

• t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015 Feb 27;5:e285. doi: 10.1038/bcj.2015.6.

  Narita T, Fukushima T et al,

• CD14(+) follicular dendritic cells in lymphoid follicles may play a role in the pathogenesis of IgG4-related disease. Biomedical Research 36, 143-153, 2015

  Satoh-Nakamura T, Fukushima T et al,

• Decreased Expression of Innate Immunity-Related Genes in Peripheral Blood Mononuclear Cells from Patients with IgG4-Related Disease. PLoS One. 2015 May 14;10(5):e0126582. doi: 10.1371/journal.pone.0126582. eCollection 2015

  Nakajima A, Fukushima T et al,

• Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice. J Immunol 192, 979-984, 2014

  Fujita Y, Fukushima T et al,

• Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53, 79-85, 2013

  Masaki Y, Fukushima T,et al,

• Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.Exp Hematol 41, 894-902, 2013

  Takamatsu H, Fukushima T et al,

• Daily 500 mg valacyclovir is effective for prevention of varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res 32: 5437-5440, 2012

  Fukushima T et al,

• Low dose cytarabine plus aclarubicin for patients with previous untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline. Anticancer Res 32: 1347-1354, 2012

  Fukushima T et al,

• A rondomized comparison of modified intermediate-dose Ara-C versus high dose Ara-C in post-remission therapy for acute myeloid leukemia. Anticancer Res 32: 643-648, 2012

  Fukushima T et al,

• Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia. Int J Hematol 96: 357-363, 2012

  Takami A, Fukushima T et al,

• Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 31: 1741-1744, 2011

  Fukushima T, et al,

• Rapid response of plasmacytoma to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma. Am J Hematol 86: 893, 2011

  Fukushima T, et al,

• Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: Once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 31: 2297-2302, 2011

  Fukushima T et al,

• DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1 - analysis of their binding with TGF- superfamily proteins. FEBS J 277: 4278-89, 2010

  Tanaka M, Fukushima T et al,

• Cisplatin Augments FAS-Mediated Apoptosis through Lipid Rafts. Anticancer Res 30: 2065-72, 2010 21. Cao Y, Fukushima T et al, Synergistic Effects of Topoisomerase I Inhibitor, SN38 on Fas-mediated Apoptosis. Anticancer Res 30: 3911-3917, 2010

  Huang CR, Fukushima T et al,

• Synergistic Effects of Topoisomerase I Inhibitor, SN38 on Fas-mediated Apoptosis. Anticancer Res 30: 3911-3917, 2010

  Cao Y, Fukushima T et al,

• Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas. Anticancer Res 30: 3791-4, 2010

  Fukushima T et al,

• MRSA-pyomyositis in a patient with acute myelogenous leukemia after intensive chemotherapy. Anticancer Res 29: 3361-4, 2009

  Fukushima T et al,

• Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome: Analysis of 64 cases of IgG4-related disorders.Ann Rheum Dis 68: 1310-5, 2009

  Masaki Y, Fukushima T et al,

• Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 89:600-10, 2009

  Masaki Y, Fukushima T et al,

• Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes. Leuk Lymph 49; 809-14, 2008

  Yamashita T, Fukushima T, Ueda T.

• Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells. Int Immunol 20: 1427-37, 2008

  Jin ZX, Fukushima T et al,

• Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patients with systemic lupus erythematosus. Lupus 17: 210-4, 2008

  Fukushima T et al,

著書

• 【共著】福島俊洋：第10章 遺伝子、その他難病における診断・治療の現状と求める医薬品・医療機器・再生医療像 第6節、特発性血小板減少性紫斑病、希少疾患用医薬品の適応拡大と事業性評価 (No.1969), 472, 株式会社 技術情報協会、東京、2018

• 【共著】福島俊洋：第2章 がん分子標的薬における副作用の疫学データと発現機序、診断・治療の現状、第21節 [1]、レチノイン酸症候群 (APL分化症候群), 254, 株式会社 技術情報協会、東京、2012